Comparisons of Quality of Life and Cardiac Performance After Complete Atrioventricular Junction Ablation and Atrioventricular Junction Modification in Patients With Medically Refractory Atrial Fibrillation  by Lee, Shih-Huang et al.
Comparisons of Quality of Life and Cardiac Performance After
Complete Atrioventricular Junction Ablation and Atrioventricular
Junction Modification in Patients With Medically Refractory
Atrial Fibrillation
SHIH-HUANG LEE, MD, SHIH-ANN CHEN, MD,* CHING-TAI TAI, MD,
CHERN-EN CHIANG, MD, ZU-CHI WEN, MD, JUN-JACK CHENG, MD,*
YU-AN DING, MD, FACC, MAU-SONG CHANG, MD
Taipei, Taiwan, Republic of China
Objectives. This study compared the long-term effects of com-
plete atrioventricular junction (AVJ) ablation with those of AVJ
modification in patients with medically refractory atrial fibrilla-
tion (AF).
Background. Comparisons between the long-term effects of AVJ
ablation with those of AVJ modification in patients with medically
refractory AF have not been systematically studied.
Methods. Sixty patients with medically refractory AF were
randomly assigned to receive complete AVJ ablation with perma-
nent pacing or AVJ modification. Subjective perception of quality
of life (QOL) was assessed by a semiquantitative questionnaire
before and 1 and 6 months after ablation. Cardiac performance
was evaluated by echocardiography and radionuclide angiography
within 24 h (baseline) and at 1 and 6 months after ablation.
Results. Both methods were associated with significant im-
provement in general QOL and a significant reduction in the
frequency of major symptoms and symptoms during attacks. The
frequency of hospital admission and emergency room visits and
antiarrhythmic drug trials significantly decreased after ablation
in both groups. However, patients after complete AVJ ablation
had a significantly greater improvement in general QOL and a
significantly reduced frequency of major symptoms and symptoms
during attacks (including palpitation, dizziness, chest oppression,
blurred vision and syncope). Left ventricular (LV) systolic func-
tion and the ability to perform activities of daily life significantly
improved after ablation in patients with depressed LV function in
both groups. All improvements after ablation or modification were
maintained over the 6-month follow-up period.
Conclusions. AVJ ablation with permanent pacing, as com-
pared with AVJ modification, had a significantly greater ability to
decrease the frequency of attacks and the extent of symptoms of
AF, and the patients who received this procedure were more
satisfied with their general well-being.
(J Am Coll Cardiol 1998;31:637–44)
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Previous reports (1–10) have demonstrated that complete
catheter ablation of the atrioventricular junction (AVJ) with
permanent pacing improved the quality of life (QOL), the
ability to perform activities of daily life (ADL) and ventricular
performance in patients with medically refractory atrial fibril-
lation (AF). Recently, some studies (11–15) have demon-
strated that radiofrequency catheter modification of atrioven-
tricular (AV) conduction could achieve control of ventricular
rate (VR) during AF without the need for pacemaker implan-
tation. However, questions arose regarding the long-term
effects of radiofrequency catheter modification of the AVJ on
QOL, symptoms of AF, ADL and left ventricular (LV) func-
tion in these patients. Furthermore, no previous studies have
compared the long-term effects of complete AVJ ablation with
those of AVJ modification in patients with medically refractory
AF. The purpose of the present study was to prospectively
compare the long-term effects on QOL and cardiac perfor-
mance after complete AVJ ablation and permanent pacing
with those after AVJ modification in patients with medically
refractory AF with or without depressed LV function.
Methods
Patients. This study included 60 patients with medically
refractory paroxysmal atrial fibrillation (PAF) or chronic atrial
fibrillation (CAF). All patients had frequent attacks of symp-
tomatic AF with rapid ventricular response documented by
electrocardiographic recordings. Patients with a standard indi-
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cation for permanent pacemaker implantation—for example,
AF with long pause or with symptomatic bradycardia—were
excluded from the study.
Electrophysiologic study and radiofrequency catheter abla-
tion. Informed consent was obtained from all patients, and the
study protocol was approved by the Human Research Com-
mittee at our institution. All patients were randomly assigned
to receive complete AVJ ablation with permanent pacing or
AVJ modification according to a random number table. As
described previously, a 7F quadripolar electrode catheter with
a 4-mm distal electrode (2- to 5-mm spacing between elec-
trodes and a deflectable tip, Mansfield, Boston Scientific) was
used to deliver radiofrequency energy (Radionic-3C, Radion-
ics); a large electrosurgical paddle (Valleylab) positioned on
the posterior chest wall served as the indifferent electrode
(15,16).
In patients who received AVJ ablation and permanent
pacing, the ablation catheter was placed across the tricuspid
valve and positioned to record the largest His bundle electro-
gram associated with the largest atrial electrogram. Energy was
delivered until complete AV block was achieved and then
continued for an additional 30 s. If no change in AV conduc-
tion was observed after 60 s of radiofrequency application, the
catheter was repositioned and a repeat attempt was made. This
procedure was repeated until complete AV block persisted for
30 min. A 5F bipolar catheter was then introduced through the
right jugular vein into the right ventricular apex for temporary
pacing. Two days after ablation, a programmable permanent
pacemaker (ventricular rate-adaptive mode) was implanted in
these patients. During the study period, the pacemaker was
programmed at a basic rate of 70 beats/min and at an activity
upper sensor rate of 120 beats/min. Pacemaker implantation
time was included in determining the procedure duration and
fluoroscopy time.
In patients who received AVJ modification, as described
previously (15), the VR of AF was measured for 1 min in the
baseline state and after a steady state effect had been reached
during the infusion of different doses of isoproterenol (2 and
4 mg/min for 10 min). The ablation catheter was initially
positioned against the posterior septum at the level of, or lower
than, the coronary sinus ostium to record a stable electrogram
for $10 s with a maximal atrial to ventricular electrographic
ratio #0.5. Radiofrequency energy was delivered for 20 s at a
power of 30 W. If there was no change in VR or no appearance
of accelerating junctional rhythm within 20 s, a higher energy
level (step-up 5 W for 20 s, up to 40 W) was delivered to the
original site. Whenever there was an abrupt lengthening of the
RR interval or appearance of the accelerating junctional
rhythm, the application of energy was immediately discontin-
ued. If the VR was still higher than the end point VR, a higher
energy level was delivered to the effective site or the ablation
site was changed. Radiofrequency energy was delivered to
three close sites of posterior and inferior regions before the
ablation catheter was repositioned progressively upward (more
superior and anterior positions) along the tricuspid annulus.
Radiofrequency energy was never delivered at the upper third
of the atrial septum, where a His bundle potential was visible.
The end point of the procedure was an average VR of ;120 to
130 beats/min or an average VR of ;70% to 75% of the
baseline VR during infusion of isoproterenol (4 mg/min) (15).
QOL. All patients were followed up for $6 months. All
kept a detailed QOL diary that included general QOL, fre-
quency of significant symptoms, symptoms during attacks and
ADL. All patients visited a special clinic at 1 and 2 weeks and
then every month to assess medication, number of hospital
admissions, emergency room visits and the QOL diary. Drugs
considered in this assessment were digoxin and any agent in
Vaughan Williams class I to IV.
Subjective perception of QOL was assessed by a semiquan-
tative questionnaire before and at 1 and 6 months after
ablation. Patients were asked to compare their general QOL,
frequency of significant symptoms, symptoms during attacks
and ADL with those before ablation. The assessment of
general QOL before and after radiofrequency catheter abla-
tion was scored as 0 5 very good, 1 5 good, 2 5 moderate, 3 5
poor, and 4 5 very bad. The frequency of AF was scored as 0 5
none, 1 5 very infrequent, 2 5 sometimes, and 3 5 very
frequent. As described previously, each patient was also asked
to quantify each of the following symptoms resulting from AF
on a score scale of 0 5 no symptoms, 1 5 mild, 2 5 moderate,
3 5 severe. The symptoms included palpitation, asthenia
(sensation of fatigue), effort dyspnea, rest dyspnea, dizziness,
chest oppression, blurred vision and syncope (0 5 none, 1 5
presyncope, 2 5 syncope) (16,17). Patients scored the impair-
ment of their ability to perform ADL before and at 1 and 6
months after ablation.
Activity limitation scores were 0 5 not limited, 1 5 mildly
limited, 2 5 moderately limited, and 3 5 severely limited. The
activities of daily life assessed were 1) bathing, 2) walking on
level surface, 3) climbing stairs, 4) carrying groceries, and 5)
vigorous exercise.
Cardiac performance. Cardiac performance was evaluated
by echocardiography and radionuclide angiography in all pa-
tients within 24 h after ablation (baseline evaluation) and at 1
and 6 months after ablation. Antiarrhythmic agents with a
negative inotropic effect were discontinued for $5 half-lives,
and amiodarone was stopped $30 days before each study of
cardiac performance (6). In patients who received AVJ abla-
Abbreviations and Acronyms
ADL 5 activities of daily life
AF 5 atrial fibrillation
AV 5 atrioventricular
AVJ 5 atrioventricular junction
CAF 5 chronic atrial fibrillation
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
PAF 5 paroxysmal atrial fibrillation
QOL 5 quality of life
VR 5 ventricular rate
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tion and permanent pacing, echocardiography and radionu-
clide angiography at three evaluations were performed during
a VR of 70 beats/min. In patients who received AVJ modifi-
cation, echocardiograms and radionuclide angiograms were
obtained during sinus rhythm in patients with PAF and during
AF in patients with CAF. In each patient, the cardiac rhythm
(sinus rhythm or AF) was the same at three evaluations, and
the difference in VR between evaluations was ,10 beats/min.
During echocardiographic study, LV end-diastolic and end-
systolic volumes were measured from the apical four-chamber
view according to Simpson’s rule (18). Images were averaged
over three to five cycles by an experienced operator who had
no knowledge of the ablation procedure. Left ventricular
ejection fraction (LVEF) was measured by technetium-99m
multigated radionuclide angiography with use of the left
anterior oblique view by a single observer who had no knowl-
edge of the ablation procedure (19). A symptom-limited
treadmill exercise test using the modified Bruce protocol was
performed before and at 1 and 6 months after ablation, if the
patients could tolerate the test.
Statistical analysis. All continuous variables are expressed
as mean value 6 SD. The chi-square test with the Yates
correction or Fisher exact test was used to assess the nonpara-
metric data, and a Student t test was used to compare
continuous variables between two groups. A two-way repeated
measures analysis of variance with the Student-Newman-Keuls
test was used to compare QOL and cardiac performance
before and at 1 and 6 months after ablation. Regression
analysis was used to assess the correlation between two vari-
ables. To assess the independent variables in predicting the
change of QOL and cardiac performance after ablation, mul-
tivariate logistic regression analysis was carried out by consid-
ering all variables identified as p % 0.25 in the univariate
analysis. The variables included for analysis were baseline
patient characteristics (age, gender, type of AF, duration of
AF, left atrial dimension, LVEF, VR in Holter recording, and
presence of other heart disease) and the baseline score for
general QOL, frequency of significant symptoms, symptoms
during attacks, ADL, number of hospital and emergency room
admissions and number of previous antiarrhythmic drugs. A p
value , 0.05 was considered statistically significant.
Results
Baseline data (Table 1). The mean age was 69 6 9 years in
patients after AVJ ablation with permanent pacing and 66 6
10 years in patients after AVJ modification. The proportion of
patients with PAF, the mean duration of symptoms suggestive
of AF and rest and maximal VR during AF were similar in the
two groups. A mean of 4.9 6 1.9 antiarrhythmic drugs for
preventing AF or decreasing VR during AF had been tried
unsuccessfully in the group after AVJ ablation and a mean of
5.3 6 2.3 antiarrhythmic drugs had been tried unsuccessfully in
the group after AVJ modification. New York Heart Associa-
tion functional class, left atrial dimension measured by echo-
cardiography and incidence of cardiovascular diseases were
similar in the two treatment groups.
Ablation results. In all patients who received AVJ ablation
and permanent pacing, complete ablation of the AV conduc-
tion system was successful and without complications. One
patient had recurrence of AV conduction within 24 h after
ablation; he had successful ablation in the second session
without recurrence of a conduction. All patients after complete
AVJ ablation with permanent pacing were discharged from the
hospital with completely paced rhythm, and none manifested
AV conduction during a mean follow-up period of 16 6 6
months (range 10 to 22). The rest and maximal paced VR 6
months after ablation were 74 6 3 and 114 6 5 beats/min,
respectively. In 4 of the 15 patients with PAF, pacemaker
syndromes were documented; these included mild dizziness in
3 patients and mild weakness in 1 patient. Twenty-eight of the
30 patients who received AVJ modification had successful
modification; the other 2 had complete AV block immediately
after the modification procedure. A permanent pacemaker
(ventricular rate-adaptive mode) was implanted in the two
patients with AV block. These two patients were included in
the analysis based on intention to treat. Late AV block or
Table 1. Baseline Data of Study Patients
Complete AVJ
Ablation
(n 5 30)
AVJ
Modification
(n 5 30)
p
Value
Age (yr) 69 6 9 66 6 10 NS
Men/women 23/7 21/9 NS
Paroxysmal AF 15 (50%) 16 (53%) NS
Duration of AF (yr) 6.3 6 1.7 5.9 6 1.6 NS
Unsuccessful drugs (no.) 4.9 6 1.9 5.3 6 2.3 NS
Heart rate (beats/min)*
Rest 130 6 16 127 6 13 NS
Maximal 172 6 18 176 6 14 NS
NYHA functional class
I 5 (17%) 4 (13%)
II 20 (66%) 19 (63%)
III 3 (10%) 5 (17%)
IV 2 (7%) 2 (7%)
LVEF (%) 51 6 6 49 6 10 NS
LA dimension (mm) 39 6 5 38 6 6 NS
Associated CV diseases
Hypertension 11 (37%) 13 (43%) NS
Ischemic heart disease 2 (7%) 2 (6%) NS
Valvular heart disease 2 (7%) 1 (3%) NS
Congenital heart disease 1 (3%) 0 (0%) NS
Radiofrequency ablation
Success rate 30 (100%) 28 (93%) NS
Recurrence rate 1 (3%) 0 NS
Complication rate 0 0 NS
Radiofrequency pulses (no.) 4 6 2 12 6 4 , 0.01
Procedure time (min) 179 6 42 163 6 74 NS
Fluoroscopy time (min) 25 6 9 40 6 11 , 0.01
*On Holter recording. Data are expressed as mean value 6 SD or number
(%) of patients. AF 5 atrial fibrillation; AVJ 5 atrioventricular junction; CV 5
cardiovascular; LA 5 left atrial; LVEF 5 left ventricular ejection fraction;
NYHA 5 New York Heart Association.
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symptomatic bradycardia was not observed in any of the
patients with successful modification during the follow-up
period (mean 15 6 5 months, range 9 to 21). The minimal, rest
and maximal values for VRs during AF 6 months after
modification were 64 6 7, 87 6 14 and 132 6 21 beats/min,
respectively. The maximal cycle length during AF was 1,052 6
123 ms. The major differences between patient groups were the
significantly higher radiofrequency pulses and longer fluoros-
copy time in patients who received AVJ modification. In both
groups, patients with CAF received warfarin sodium (Couma-
din) and those with PAF received aspirin during follow-up.
Early or late complications (including sudden death and stroke
or thromboembolism related to AF) did not occur in either
group.
Comparisons of AVJ ablation and AVJ modification. QOL
(Table 2). In the two groups, general QOL improved signifi-
cantly and the frequency of major symptoms decreased signif-
icantly at 1 and 6 months of follow-up. After complete AVJ
ablation, all the symptoms during attacks decreased signifi-
cantly at 1 and 6 months of follow-up. After AVJ modification,
symptom scores including those for palpitation, asthenia, effort
dyspnea and rest dyspnea during attacks improved significantly
at 1 and 6 months of follow-up; however, symptom scores for
dizziness, chest oppression, blurred vision and syncope re-
mained unchanged. The ability to bathe, walk on level surfaces
and climb stairs improved significantly in the two groups at 1
and 6 months of follow-up. Although the ability to carry
groceries and perform vigorous exercise remained unchanged,
the pooled score of ADL changed significantly at 1 and 6
months of follow-up in the two groups. The consumption of
health care resources, including frequency of hospital admis-
sion and emergency room visits for AF and entrance into
antiarrhythmic drug trials, decreased significantly 6 months
after AVJ ablation or modification. During the study period,
cardiac drugs with negative chronotropic effects were contin-
ued because of other cardiovascular diseases in 11 (37%) of
the 30 patients after complete AVJ ablation; these drugs
included atenolol in 5, verapamil in 3 and digoxin in 3. Twelve
(40%) of the 30 patients after AVJ modification received drugs
with negative chronotropic effects; these drugs included ateno-
lol in 5, verapamil in 2 and digoxin in 5.
Comparisons between the two treatment groups showed
that each variable of QOL obtained before AVJ ablation or
modification was similar. The 1- and 6-month follow-up studies
showed that patients who received complete AVJ ablation had
significantly greater improvement in scores for general QOL,
frequency of significant symptoms and symptoms during at-
tacks, including palpitation, dizziness, chest oppression,
blurred vision and syncope, than did those who received AVJ
modification. However, the symptom scores for asthenia, effort
dyspnea and rest dyspnea during attacks were similar in both
groups at 1 and 6 months of follow-up, as were the symptom
scores for ADL. No variable in consumption of health care
resources was significantly different between the two groups at
6 months of follow-up.
Table 2. Comparisons of Quality of Life Scores Between Patients After Atrioventricular Junction Ablation and Atrioventricular
Junction Modification
Atrioventricular Junction Ablation Atrioventricular Junction Modification
Before
Ablation 1 mo 6 mo
Before
Ablation 1 mo 6 mo
Scores*
General quality of life 3.2 6 1.2 1.1 6 0.7† 1.0 6 0.8‡ 3.1 6 1.1 1.7 6 0.8§† 1.7 6 0.7§‡
Frequency of significant symptoms 2.2 6 0.9 0.7 6 0.9† 0.7 6 0.8‡ 2.3 6 0.8 1.3 6 0.9§† 1.4 6 0.9§‡
Symptoms during attacks 12.9 6 2.0 6.2 6 1.8† 6.4 6 1.7‡ 13.1 6 2.1 9.0 6 1.9§† 9.0 6 2.1§‡
Palpitation 2.4 6 0.8 0.4 6 0.5† 0.5 6 0.5‡ 2.3 6 0.9 1.2 6 0.6§† 1.3 6 0.7§‡
Asthenia 2.1 6 0.8 1.1 6 0.6† 1.0 6 0.6‡ 2.2 6 0.7 1.3 6 0.6† 1.2 6 0.7‡
Effort dyspnea 2.0 6 0.7 1.2 6 0.6† 1.3 6 0.7‡ 2.0 6 0.7 1.2 6 0.7† 1.2 6 0.8‡
Rest dyspnea 1.6 6 0.5 0.9 6 0.7† 1.0 6 0.6‡ 1.7 6 0.8 1.1 6 0.7† 1.1 6 0.8‡
Dizziness 1.7 6 0.8 1.0 6 0.7† 1.0 6 0.7‡ 1.6 6 0.8 1.4 6 0.7§ 1.4 6 0.8\
Chest oppression 1.4 6 0.6 0.7 6 0.8† 0.8 6 0.7‡ 1.4 6 0.7 1.1 6 0.7\ 1.2 6 0.8§
Blurred vision 1.0 6 0.5 0.6 6 0.6† 0.6 6 0.5‡ 1.1 6 0.8 1.0 6 0.6§ 1.0 6 0.6§
Syncope 0.7 6 0.5 0.3 6 0.5† 0.2 6 0.4‡ 0.8 6 0.6 0.7 6 0.6§ 0.6 6 0.5§
Activities of daily life 7.7 6 1.9 6.0 6 1.9† 5.9 6 1.8‡ 7.6 6 1.8 6.2 6 1.7† 6.1 6 1.7‡
Bathing 0.8 6 0.6 0.4 6 0.5† 0.3 6 0.5‡ 0.9 6 0.5 0.5 6 0.5¶ 0.4 6 0.5‡
Walking on level surfaces 1.2 6 0.7 0.8 6 0.5¶ 0.7 6 0.4‡ 1.3 6 0.7 0.9 6 0.6¶ 0.7 6 0.6‡
Climbing stairs 1.6 6 0.7 1.1 6 0.8† 1.2 6 0.8# 1.5 6 0.8 1.0 6 0.6† 1.1 6 0.7#
Carrying groceries 1.9 6 0.9 1.7 6 0.9 2.0 6 0.9 2.0 6 0.9 1.8 6 0.8 1.8 6 0.8
Vigorous exercise 2.2 6 1.1 2.0 6 1.2 2.0 6 1.2 2.1 6 0.9 2.0 6 0.9 2.1 6 1.1
Hospital admission (times/yr) 2.4 6 2.5 0.2 6 0.5‡ 2.5 6 3.0 0.4 6 0.7‡
ER visit (times/yr) 3.0 6 3.8 0.3 6 0.6‡ 2.9 6 3.5 0.3 6 0.6‡
Antiarrhythmic drugs (no.) 4.7 6 3.2 0.3 6 0.5‡ 4.5 6 2.7 0.4 6 0.5‡
*See Methods for description of specific scores. †p , 0.01, ¶p , 0.05, before ablation versus 1 month. ‡p , 0.01, **p , 0.05, before ablation versus 6 months. §p ,
0.01, \p , 0.05, atrioventricular junction ablation versus atrioventricular junction modification. Data are expressed as mean value 6 SD. ER 5 emergency room.
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Cardiac performance. Twenty-five of the 30 patients who
received complete AVJ ablation and 24 of the 30 patients who
received AVJ modification had a satisfactory two-dimensional
echocardiogram available for analysis. In both groups, LV
end-diastolic dimension was unchanged, LV end-systolic di-
mension was significantly decreased and LVEF was signifi-
cantly increased at 1 and 6 months of follow-up. Furthermore,
LVEF measured by radionuclide angiography was significantly
increased at 1 and 6 months after complete AVJ ablation or
AVJ modification (Table 3). There was a strong relation
between the LVEF measured by radionuclide angiography and
the results obtained by two-dimensional echocardiography
(r 5 0.91, p , 0.05). Baseline and 1- and 6-month follow-up
studies showed that LV end-diastolic dimension, LV end-
systolic dimension and LVEF measured by echocardiography
and by radionuclide angiography were similar in the two
groups (Table 3).
Twenty-eight of the 60 patients could not complete the
exercise test before ablation because of claudication (5 pa-
tients), asthenia (10 patients), dyspnea (6 patients) and chest
pressure (7 patients). Fifteen of the 30 patients who received
AVJ ablation and permanent pacing completed the treadmill
exercise tests; their mean exercise time was 4.2 6 0.6 min
before ablation and 6.1 6 0.5 min 1 month (p , 0.01) and
5.8 6 0.4 min 6 months after ablation (p , 0.01). The mean
maximal VR was 156 6 15 beats/min before and 114 6
5 beats/min 1 month (p , 0.01) and 113 6 6 beats/min 6
months after ablation (p , 0.01). Seventeen of the 30 patients
who received AVJ modification completed the treadmill exer-
cise tests; their mean exercise time was 4.4 6 0.5 min before
ablation and 6.2 6 0.6 min 1 month (p , 0.01) and 6.0 6
0.7 min 6 months after ablation (p , 0.01). The mean maximal
VR was 158 6 17 beats/min before and 137 6 14 beats/min 1
month (p , 0.01) and 135 6 17 beats/min 6 months after
ablation (p , 0.01). The mean exercise time was similar
between the two groups before and 1 and 6 months after
ablation.
Subgroup analysis based on LV function. Sixteen of the 30
patients who received complete AVJ ablation and 17 of the 30
patients who received AVJ modification had a baseline LV
ejection fraction ^50% measured by radionuclide angiogra-
phy. The general QOL and scores for frequency of significant
symptoms and symptoms during attacks of AF improved
significantly after complete AVJ ablation or AVJ modification,
independent of LV function. The consumption of health care
resources decreased significantly after complete AVJ ablation
or AVJ modification, independent of LV function. The ability
to perform ADL was not changed in patients with a baseline
LVEF ^50%, but the capacity to bathe, walking on level
surfaces and climb stairs improved significantly after AVJ
ablation or modification in patients with a baseline LVEF
,50%. No variable of cardiac performance was changed in
patients with a baseline LVEF ^50%, but LV end-systolic
dimension measured by echocardiography decreased signifi-
cantly and LVEF measured by echocardiography and radionu-
clide angiography increased significantly after AVJ ablation or
modification in patients with a baseline LVEF ,50%. In
patients with a baseline LVEF ,50%, the percent change in
pooled score of ADL correlated with the percent change in
LVEF obtained at 6 months after complete AVJ ablation (r 5
20.84, p , 0.01, slope 5 0.71) and AVJ modification (r 5
20.83, p , 0.01, slope 5 0.76), and the slope of the regression
line was similar between the two subgroups (p 5 0.31).
Factors influencing improvement in QOL and cardiac
performance. Patients with PAF had an improvement in QOL
and cardiac performance after AVJ ablation with permanent
pacing similar to that of patients with CAF (Table 4). The
improved effects of AVJ modification on QOL and cardiac
performance in patients with PAF were also similar to those of
patients with CAF (Table 5). Furthermore, none of the
analyzed factors could independently predict improvement in
QOL and cardiac performance after AVJ ablation or AVJ
modification.
Discussion
Major findings. Compared with AVJ modification, AVJ
ablation with permanent pacing had a significantly greater
ability to decrease the frequency of attacks and extent of
symptoms of AF, and the patients who received this procedure
Table 3. Comparisons of Cardiac Performance Between Patients After Atrioventricular Junction
Ablation and Atrioventricular Junction Modification
Atrioventricular Junction Ablation
Atrioventricular Junction
Modification
Before 1 mo 6 mo Before 1 mo 6 mo
Echocardiography
LVEDD (mm) 53 6 8 51 6 9 51 6 9 53 6 7 52 6 8 51 6 8
LVESD (mm) 37 6 6 34 6 7* 33 6 6† 38 6 7 35 6 6* 34 6 8†
LVEF (%) 50 6 6 55 6 6‡ 57 6 7§ 49 6 8 55 6 7‡ 55 6 7§
Radionuclide angiography
LVEF (%) 50 6 7 56 6 7‡ 58 6 6§ 49 6 8 54 6 7‡ 56 6 9§
*p , 0.05, ‡p , 0.01, before versus 1 month. †p , 0.05, §p , 0.01, before versus 6 months. Data are expressed as
mean value 6 SD. LVEDD 5 left ventricular end-diastolic dimension; LVEF 5 left ventricular ejection fraction;
LVESD 5 left ventricular end-systolic dimension.
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were more satisfied with their general well-being. However,
both AVJ ablation with permanent pacing and AVJ modifica-
tion were effective in improving general QOL, decreasing the
frequency of significant symptoms, alleviating symptoms dur-
ing attacks and decreasing the consumption of health care
resources in patients with medically refractory AF. Further-
more, in patients with depressed LV function, both methods
were similarly efficacious in improving LVEF and ADL scores.
These improvements in QOL and cardiac performance oc-
curred within 1 month after ablation and they were maintained
through 6 months after the procedure.
Comparisons between AVJ ablation and AVJ modification.
Quality of life. Kay et al. (2) first reported that QOL could be
improved in 12 consecutive patients with PAF after catheter
ablation using direct current. Brignole et al. (8) showed that
radiofrequency ablation of AVJ with permanent pacing signif-
icantly improved QOL and ADL score in 23 patients with CAF
and flutter. Fitzpatrick et al. (9) recently reported positive
outcomes in terms of QOL, ADL and consumption of health
care resources after radiofrequency ablation of AVJ with
permanent pacing in 107 patients who had established CAF or
PAF. In the present study, AVJ ablation with permanent
pacing had similar effects as in the previous studies.
The present study demonstrated that AVJ modification
significantly improved general QOL and decreased the fre-
quency of significant symptoms and consumption of health
care resources. The decrease in VR during AF after modifi-
cation resulted in the lessening of symptoms, such as palpita-
Table 4. Comparisons of Quality of Life and Cardiac Performance Between Patients With Paroxysmal Atrial Fibrillation and Chronic Atrial
Fibrillation After Atrioventricular Junction Ablation
Paroxysmal Atrial Fibrillation Chronic Atrial Fibrillation
Before 1 mo 6 mo Before 1 mo 6 mo
Scores*
General quality of life 3.0 6 1.1 1.0 6 0.7† 1.1 6 0.6‡ 3.3 6 1.3 1.2 6 0.8† 1.0 6 0.9‡
Frequency of significant symptoms 2.4 6 1.0 0.6 6 0.8† 0.8 6 0.8‡ 2.0 6 0.7 0.9 6 0.9† 0.7 6 0.7‡
Symptoms during attacks 13.2 6 2.1 5.9 6 2.0† 6.0 6 1.8‡ 12.5 6 1.9 6.4 6 1.6† 6.7 6 1.6‡
Activities of daily life 7.5 6 1.7 6.1 6 1.9† 6.0 6 1.6‡ 8.0 6 2.1 5.8 6 2.0† 5.7 6 1.9‡
Hospital admission (times/yr) 2.1 6 2.4 0.3 6 0.6‡ 2.6 6 2.5 0.2 6 0.5‡
ER visit (times/yr) 2.7 6 3.5 0.4 6 0.5‡ 3.2 6 4.1 0.3 6 0.6‡
Antiarrhythmic drugs (no.) 5.0 6 3.6 0.4 6 0.6‡ 4.4 6 2.7 0.3 6 0.5‡
Echocardiography
LVEDD (mm) 52 6 7 50 6 8 50 6 10 54 6 8 53 6 10 52 6 9
LVESD (mm) 37 6 5 33 6 7§ 33 6 5\ 38 6 6 34 6 6§ 34 6 6\
LVEF (%) 50 6 6 56 6 7† 57 6 8‡ 49 6 5 55 6 6† 56 6 6‡
Radionuclide angiography
LVEF (%) 50 6 7 56 6 7† 58 6 7‡ 49 6 7 55 6 8† 57 6 6‡
*See Methods for description of specific scores. †p , 0.01, §p , 0.05, before versus 1 month. ‡p , 0.01, \p , 0.05, before versus 6 months. Data are expressed
as mean value 6 SD. Abbreviations as in Tables 2 and 3.
Table 5. Comparisons of Quality of Life and Cardiac Performance Between Patients With Paroxysmal Atrial Fibrillation and Chronic Atrial
Fibrillation After Atrioventricular Junction Modification
Paroxysmal Atrial Fibrillation Chronic Atrial Fibrillation
Before 1 mo 6 mo Before 1 mo 6 mo
Scores*
General quality of life 3.2 6 1.1 1.8 6 1.0† 1.8 6 0.8‡ 3.1 6 1.2 1.6 6 0.7† 1.7 6 0.7‡
Frequency of significant symptoms 2.5 6 0.9 1.4 6 1.0† 1.5 6 0.9‡ 2.1 6 0.7 1.2 6 0.8† 1.4 6 0.8‡
Symptoms during attacks 12.8 6 2.2 8.7 6 2.0† 8.8 6 2.1‡ 13.3 6 1.9 9.2 6 1.8† 9.1 6 2.2‡
Activities of daily life 7.7 6 1.6 5.9 6 1.6† 6.0 6 1.8‡ 8.0 6 2.1 6.4 6 1.8† 6.2 6 1.7‡
Hospital admission (times/year) 2.4 6 3.1 0.5 6 0.8‡ 7.6 6 2.8 0.4 6 0.7‡
ER visit (times/year) 2.6 6 3.4 0.3 6 0.5‡ 3.1 6 3.6 0.4 6 0.7‡
Antiarrhythmic drugs (no.) 4.7 6 2.9 0.4 6 0.6‡ 4.3 6 2.5 0.5 6 0.5‡
Echocardiography
LVEDD (mm) 54 6 7 53 6 8 52 6 7 53 6 6 51 6 8 50 6 8
LVESD (mm) 38 6 6 34 6 5§ 33 6 8\ 39 6 7 35 6 6§ 34 6 7\
LVEF (%) 49 6 7 55 6 6† 56 6 7‡ 48 6 8 55 6 7† 55 6 6‡
Radionuclide angiography
LVEF (%) 50 6 6 55 6 7† 57 6 9‡ 48 6 9 54 6 8† 56 6 8‡
*See Methods for description of specific scores. †p , 0.01, §p , 0.05, before versus 1 month. ‡p , 0.01, \p , 0.05, before versus 6 months. Data are expressed
as mean value 6 SD. Abbreviations as in Tables 2 and 3.
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tion, asthenia, effort dyspnea and rest dyspnea. However,
symptoms including dizziness, chest oppression, blurred vision
and syncope did not significantly lessen after AVJ modifica-
tion.
Morady et al. (20) also demonstrated that ;70% of patients
had lessening of symptoms after AVJ modification; however,
their study patients were not randomized to receive AVJ
ablation or modification therapy (20). Furthermore, the
present study used a score scale to assess the symptoms
resulting from AF. We demonstrated that patients after AVJ
ablation with permanent pacing, as compared with AVJ mod-
ification, had a significantly greater lessening of the frequency
and symptoms of AF including palpitation, dizziness, chest
oppression, blurred vision and syncope. The patients who
received AVJ ablation with permanent pacing became asymp-
tomatic, perhaps because of better control of VR and regular-
ization of ventricular rhythm during AF; the patients who
received AVJ modification remained symptomatic, perhaps
because of the irregular ventricular rhythm of AF. Further-
more, the patients with PAF remained symptomatic, perhaps
because of their awareness of the onset and offset of an episode
after AVJ modification. The present study also demonstrated
that in patients with depressed LV function, both treatments
had a similar efficacy in improving the capacity to perform
ADL including bathing, walking on level surfaces and carrying
groceries. By quantifying and correlating the changes in LV
performance and ADL, this study also offered a direct expla-
nation for the increase in performance of ADL after AVJ
ablation with permanent pacing or AVJ modification.
Cardiac performance. In this study, echocardiographic mea-
surements at three evaluations were obtained during ventric-
ular pacing at the same VR in patients after AVJ ablation and
permanent pacing. Therefore, abnormal septal motion during
right ventricular pacing should be of minor significance to our
results (21). Patients after AVJ modification had the same
atrial rhythm and a similar VR (difference ,10 beats/min) at
three evaluations; this study design excluded VR as an artifact
of initially depressed LVEF. Furthermore, the evaluation of
baseline myocardial function within 24 h after ablation seemed
applicable, because substantial changes in myocardial mechan-
ics might not be expected until day 10 after abolition of the
tachycardia (22,23). Although the effects of oral amiodarone
might exist after discontinuation for 30 days (seven patients),
this drug appeared to have little if any negative inotropic action
(24).
Patients with baseline depressed LV function had a signif-
icant improvement in LVEF after AVJ modification. This
observation supported the view that baseline LV dysfunction
might result from rapid VR and that control of the rapid VR
would lead to subsequent improvement in ventricular function.
Several mechanisms of tachycardia-induced LV dysfunction
have been proposed (25–28), including myocardial ischemia
with depressed contractility, depletion of high energy phos-
phate stores, activation of the sympathetic nervous system and
renin-angiotensin system and depletion of atrial natriuretic
factor.
Compared with AVJ modification, AVJ ablation with per-
manent pacing had the advantages of better control of rapid
VR and regularization of ventricular rhythm; however, it had
the disadvantages of asynergic ventricular contraction and the
loss of AV synchrony during sinus rhythm in patients with
PAF. Several recent studies (29,30) have emphasized that right
ventricular apical pacing might worsen LV function in patients
with baseline depressed LV function. Some studies (31,32)
have demonstrated that irregularity of ventricular rhythm,
independent of VR, might also contribute to impairment of
cardiac function during AF. Our results suggest that the effects
of complete AVJ ablation with permanent pacing on cardiac
performance were similar to those of AVJ modification in
patients with depressed LV function.
Study limitations. Several limitations to this study must be
recognized. 1) A ventricular rate-adaptive mode pacemaker
was implanted in all patients after complete AVJ ablation.
Dual-chamber rate-responsive pacemakers will maintain nor-
mal AV synchrony during periods of sinus rhythm in some
patients with PAF. 2) The QOL instruments used have not
been rigorously validated for this patient group. 3) Whether
the present results will be maintained over a longer follow-up
period is unknown. 4) Although the initial study design in-
cluded a treadmill exercise test before and after ablation, only
half of the patients in this study were tolerant of the exercise
test before ablation. 5) Anxiety regarding the sudden and
unpredictable onset of severe symptoms characteristic of PAF
is likely to have been the major reason for self-imposed
limitations in performing ADL, affecting the QOL of the study
patients. Similar changes in QOL and performance of ADL
may not occur in less symptomatic patient groups. 6) We did
not have a control group of patients with similar AF treated
without catheter ablation. However, it would be difficult to
withhold catheter ablation from patients with medically refrac-
tory AF and rapid VR. 7) Participants who undergo an invasive
procedure may report improvements in QOL simply as a result
of being part of a treatment group. 8) A coexisting chronic
condition such as arthritis and congestive heart failure may
limit the ability to perform ADL in these old patients (10,33).
Conclusions. The present study suggests that both AVJ
ablation with permanent pacing and AVJ modification are safe
and effective means of improving general QOL and cardiac
performance in patients with medically refractory AF. These
improvements occurred within 1 month after ablation and
were maintained through 6 months after the procedure. Fur-
thermore, AVJ ablation with permanent pacing had a signifi-
cantly greater effect than that of AVJ modification in decreas-
ing the frequency of attacks and extent of symptoms of AF, and
the patients who received this procedure were more satisfied
with their general well-being.
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